A Study to Investigate BMS-986165 and Methotrexate in Healthy Male Patients

An Open-Label, Single-Sequence Study to Investigate the Effects of BMS-986165 on the Single-Dose Pharmacokinetics of Methotrexate in Healthy Male Subjects

The purpose of this study is to investigate effects of BMS-986165 on blood levels of methotrexate given as a single dose in healthy male patients.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Body Mass Index (BMI): 18.0 - 32.0 kg/m2
• Normal renal function at screening

Exclusion Criteria:

• Any medical condition that presents a potential risk to the participant and/or that may compromise the objectives of the study, including active, or history of, liver disease
• Any contraindication indicated in the MTX package insert
• History or presence of chronic bacterial or viral infection
• History or presence of an autoimmune disorder
• Any significant acute or chronic medical illness
• Active TB requiring treatment or documented latent TB within the previous 3 years
• Current or recent (within 3 months of study treatment administration) gastrointestinal disease that could affect absorption

Other protocol defined inclusion/exclusion criteria could apply